argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
|Articles|June 13, 2019
Aptar Acquires Nanopharm and Gateway Analytical
Author(s)BioPharm International Editors
The acquisitions, totaling $50 million, are expected expand Aptar Pharma’s service offerings to support complex product development.
Advertisement
On June 10, 2019, AptarGroup announced that it has acquired two pharmaceutical services companies, Nanopharm and Gateway Analytical, for a combined price of approximately $50 million.
Nanopharm, located in Newport, UK, is a provider of orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, PA, provides particulate detection and predictive analytical services to customers developing injectable medicines.
Both acquisitions bring complementary analytical, testing, and development services for all stages of drug development and commercialization. The acquisitions are part of Aptar’s strategy to broaden its service portfolio to support complex product development. Aptar states that the expanded services platform will enable its pharma arm to collaborate earlier with customers to support their complex drug formulations and delivery requirements.
“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” commented Gael Touya, president of Aptar Pharma, in a company press release. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial, and market-launch phases of drug development.”
Source:
Advertisement
Related to this article
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5